These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

395 related items for PubMed ID: 15477632

  • 21. The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy.
    Molina JR, Adjei AA.
    Clin Lung Cancer; 2003 Jul; 5(1):21-7. PubMed ID: 14596699
    [Abstract] [Full Text] [Related]

  • 22. Pemetrexed therapy for malignant pleural mesothelioma.
    Puto K, Garey JS.
    Ann Pharmacother; 2005 Apr; 39(4):678-83. PubMed ID: 15755794
    [Abstract] [Full Text] [Related]

  • 23. Pemetrexed-associated urticarial vasculitis.
    Lopes G, Vincek V, Raez LE.
    Lung Cancer; 2006 Feb; 51(2):247-9. PubMed ID: 16360237
    [Abstract] [Full Text] [Related]

  • 24. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
    Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, Blatter J, Adachi S, Hanauske A, Manegold C.
    J Clin Oncol; 2008 Apr 01; 26(10):1698-704. PubMed ID: 18375898
    [Abstract] [Full Text] [Related]

  • 25. A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours.
    Nakagawa K, Kudoh S, Matsui K, Negoro S, Yamamoto N, Latz JE, Adachi S, Fukuoka M.
    Br J Cancer; 2006 Sep 18; 95(6):677-82. PubMed ID: 16940981
    [Abstract] [Full Text] [Related]

  • 26. [Update of pemetrexed in thoracic oncology].
    Brechot JM, Morère JF.
    Bull Cancer; 2007 Sep 18; 94 Spec No Actualites():S139-41. PubMed ID: 17845984
    [Abstract] [Full Text] [Related]

  • 27. A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma.
    Chen JS, Chao Y, Bang YJ, Roca E, Chung HC, Palazzo F, Kim YH, Myrand SP, Mullaney BP, Shen LJ, Linn C.
    Anticancer Drugs; 2010 Sep 18; 21(8):777-84. PubMed ID: 20634689
    [Abstract] [Full Text] [Related]

  • 28. Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy.
    Villela LR, Stanford BL, Shah SR.
    Pharmacotherapy; 2006 May 18; 26(5):641-54. PubMed ID: 16637794
    [Abstract] [Full Text] [Related]

  • 29. The role of Alimta in the treatment of malignant pleural mesothelioma: an overview of preclinical and clinical trials.
    Hanauske AR.
    Lung Cancer; 2004 Aug 18; 45 Suppl 1():S121-4. PubMed ID: 15261444
    [Abstract] [Full Text] [Related]

  • 30. Clinical Experience With Pemetrexed in Breast Cancer.
    Martin M.
    Semin Oncol; 2006 Feb 18; 33(Suppl 2):S15-8. PubMed ID: 16472713
    [Abstract] [Full Text] [Related]

  • 31. Alteration of pemetrexed excretion in the presence of acute renal failure and effusions: presentation of a case and review of the literature.
    Brandes JC, Grossman SA, Ahmad H.
    Cancer Invest; 2006 Feb 18; 24(3):283-7. PubMed ID: 16809156
    [Abstract] [Full Text] [Related]

  • 32. Nursing considerations for administering pemetrexed (Alimta) in combination with cisplatin for malignant pleural mesothelioma.
    Orbaugh KK.
    Clin J Oncol Nurs; 2004 Jun 18; 8(3):242-7. PubMed ID: 15208818
    [Abstract] [Full Text] [Related]

  • 33. [Pemetrexed: from preclinic to clinic].
    Lansiaux A, Lokiec F.
    Bull Cancer; 2007 Jun 18; 94 Spec No Actualites():S134-8. PubMed ID: 17845983
    [Abstract] [Full Text] [Related]

  • 34. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.
    Kane RC, Farrell AT, Sridhara R, Pazdur R.
    Clin Cancer Res; 2006 May 15; 12(10):2955-60. PubMed ID: 16707588
    [Abstract] [Full Text] [Related]

  • 35. Pemetrexed in malignant pleural mesothelioma.
    Gatzemeier U.
    Oncology (Williston Park); 2004 Nov 15; 18(13 Suppl 8):26-31. PubMed ID: 15655933
    [Abstract] [Full Text] [Related]

  • 36. Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck.
    Pivot X, Raymond E, Laguerre B, Degardin M, Cals L, Armand JP, Lefebvre JL, Gedouin D, Ripoche V, Kayitalire L, Niyikiza C, Johnson R, Latz J, Schneider M.
    Br J Cancer; 2001 Sep 01; 85(5):649-55. PubMed ID: 11531245
    [Abstract] [Full Text] [Related]

  • 37. Pemetrexed and cisplatin in patients with advanced gastric cancer: a Korean cancer study group multicenter phase II study.
    Kim YH, Chung HC, Kang WK, Park SR, Kim CS, Kim TY, Shin SW, Park BJ, Cha SJ, Bang YJ.
    Cancer Chemother Pharmacol; 2008 Jul 01; 62(2):263-70. PubMed ID: 17960386
    [Abstract] [Full Text] [Related]

  • 38. Pemetrexed: a novel antifolate agent enters clinical practice.
    Kut V, Patel JD, Argiris A.
    Expert Rev Anticancer Ther; 2004 Aug 01; 4(4):511-22. PubMed ID: 15270656
    [Abstract] [Full Text] [Related]

  • 39. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.
    Jänne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Ye Z, Monberg MJ, Obasaju CK, Pemetrexed expanded access program investigators.
    J Thorac Oncol; 2006 Jul 01; 1(6):506-12. PubMed ID: 17409909
    [Abstract] [Full Text] [Related]

  • 40. Approval summary: pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancer.
    Cohen MH, Justice R, Pazdur R.
    Oncologist; 2009 Sep 01; 14(9):930-5. PubMed ID: 19737998
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.